0      0


JL1101ES - JL1101ES: Adjuvant therapy with nivolumab versus placebo in patients with resected stage IIB/C melanoma (CheckMate 76K)


‐ Oct 30, 2023 10:00am

Full author listing

Georgina V. Long, BSc, PhD Melanoma Institute Australia, University of Sydney, Royal North Shore and Mater Hospitals, New South Wales, Australia; Michele Del Vecchio, MD, IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Jeffrey Weber, MD, PhD, NYU Langone Medical Center, New York, NY, USA; Christoph Hoeller, MD, PhD, Medizinische Universität Wien, Vienna, Austria; Jean-Jacques Grob, MD, Hôpital de la Timone, Marseille, France; Peter Mohr, MD, Elbe Klinikum Buxtehude, Buxtehude, Germany; Stephan Grabbe, MD, University of Mainz Medical Center, Mainz, Germany; Caroline Dutriaux, MD, PhD, Hôpital Saint André, Bordeaux, France; Vanna Chiarion-Sileni, MD, Istituto Oncologico Veneto IRCCS, Padova, Italy; Jacek Ma Oncology, Poznan University of Medical Sciences, Poznan, Poland; Piotr Rutkowski, MD, Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, Poland; Petr Arenberger, MD, PhD, DrSc, MBA, Charles University Third Faculty of Medicine and University Hospital of Královské Vinohrady, Prague, Czech Republic; Gaëlle Quéreux, Professor, Nantes University Hospital, Nantes, France; Tarek Meniawy, MBBS, FRACP, PhD, Sir Charles Gairdner Hospital, Perth, WA, Australia; Paolo A. Ascierto, MD, Istituto Nazionale Tumori IRCCS “Fondazione G. Pascale”, Naples, Italy; Piyush Durani, MD, MA, Bristol Myers Squibb, Princeton, NJ, USA; Maurice Lobo, MS, PharmD, Bristol Myers Squibb, Princeton, NJ, USA; Federico Campigotto, Bristol Myers Squibb, Princeton, NJ, USA; Brian Gastman, MD, Cleveland Clinic Foundation, Cleveland, OH, USA; John M. Kirkwood, MD, UPMC Hillman Cancer Center, Pittsburgh, PA, USA